We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 12,246 | 14:00:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
Hot Features
Premium
RNS Number:4574Q
Celsis International PLC
01 February 2007
STOCK EXCHANGE ANNOUNCEMENT
FOR RELEASE: 1 February 2007
CELSIS INTERNATIONAL PLC
("Celsis" or "the Company")
TOTAL VOTING RIGHTS
1 February 2007: Celsis International plc, the life sciences products and
laboratory services company, today announces that in conformity with the
Transparency Directive's transitional provision 6 Celsis' capital consists of
22,483,043 ordinary shares of 5p each ("Ordinary Shares") with voting rights.
386,500 Ordinary Shares are held in treasury. Therefore, the total number of
voting rights in Celsis is 22,096,543.
The above figure (22,096,543 Ordinary Shares) may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, Celsis
under the FSA's Disclosure and Transparency Rules.
For further information please contact:
Celsis International plc Tel: 01638 600 151
Christian Madrolle, Finance Director & Company Secretary
Jenny Parsons, Corporate Communications
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAAFFDAKXEFE
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
